Table 4.
Comparison of CIMP, MSI, and BRAF in proximal and distal colon and rectal cases
| Proximal | Distal | Rectal | |||||
|---|---|---|---|---|---|---|---|
| N | (percent) | N | (percent) | N | (percent) | p-valuea | |
| Cases with CIMP statusb | 607 | (100.0) | 595 | (100.0) | 889 | (100.0) | |
| CIMP- | 359 | (59.1) | 518 | (87.1) | 783 | (88.1) | |
| CIMP+ | 248 | (40.9) | 77 | (12.9) | 106 | (11.9) | <0.0001 |
| Cases with MLH1 status | 587 | (100.0) | 577 | (100.0) | 909 | (100.0) | |
| MLH1- | 485 | (82.6) | 560 | (97.1) | 899 | (98.9) | |
| MLH1 + | 102 | (17.4) | 17 | (3.0) | 10 | (1.1) | <0.0001 |
| Cases with p16 status | 618 | (100.0) | 606 | (100.0) | 946 | (100.0) | |
| p16- | 471 | (76.2) | 558 | (92.1) | 868 | (91.8) | |
| p16+ | 147 | (23.8) | 48 | (7.9) | 78 | (8.3) | <0.0001 |
| Cases with MINT1 status | 608 | (100.0) | 601 | (100.0) | 920 | (100.0) | |
| MINT1- | 442 | (72.7) | 561 | (93.3) | 884 | (96.1) | |
| MINT1 + | 166 | (27.3) | 40 | (6.7) | 36 | (3.9) | <0.0001 |
| Cases with MINT2 status | 613 | (100.0) | 602 | (100.0) | 906 | (100.0) | |
| MINT2- | 380 | (62.0) | 482 | (80.1) | 727 | (80.2) | |
| MINT2+ | 233 | (38.0) | 120 | (19.9) | 179 | (19.8) | <0.0001 |
| Cases with MINT31 status | 590 | (100.0) | 599 | (100.0) | 913 | (100.0) | |
| MINT31- | 319 | (54.1) | 489 | (81.6) | 740 | (81.1) | |
| MINT31+ | 271 | (45.9) | 110 | (18.4) | 173 | (19.0) | <0.0001 |
| Number of markers methylated | |||||||
| 0 | 243 | (40.0) | 383 | (64.4) | 594 | (66.8) | |
| 1 | 116 | (19.1) | 135 | (22.7) | 189 | (21.3) | |
| 2 | 87 | (14.3) | 48 | (8.1) | 67 | (7.5) | |
| 3 | 61 | (10.1) | 17 | (2.9) | 28 | (3.2) | |
| 4 | 62 | (10.2) | 10 | (1.7) | 10 | (1.1) | |
| 5 | 38 | (6.3) | 2 | (0.3) | 1 | (0.1) | <0.0001 |
| CIMP- cases with MSI status | 345 | (100.0) | 501 | (100.0) | 779 | (100.0) | |
| MSI- | 319 | (92.5) | 485 | (96.8) | 766 | (98.3) | |
| MSI+ | 26 | (7.5) | 16 | (3.2) | 13 | (1.7) | <0.0001 |
| CIMP+ cases with MSI status | 243 | (100.0) | 74 | (100.0) | 105 | (100.0) | |
| MSI- | 138 | (56.8) | 67 | (90.5) | 101 | (96.2) | |
| MSI+ | 105 | (43.2) | 7 | (9.5) | 4 | (3.8) | <0.0001 |
| CIMP- cases with BRAF status | 328 | (100.0) | 485 | (100.0) | 768 | (100.0) | |
| BRAF- | 319 | (97.3) | 482 | (99.4) | 760 | (99.0) | |
| BRAF+ | 9 | (2.7) | 3 | (0.6) | 8 | (1.0) | 0.06 |
| CIMP+ cases with BRAF status | 231 | (100.0) | 73 | (100.0) | 102 | (100.0) | |
| BRAF- | 155 | (67.1) | 58 | (79.5) | 84 | (82.4) | |
| BRAF+ | 76 | (32.9) | 15 | (20.5) | 18 | (17.7) | <0.01 |
a
Mantel-Haenszel chi-squared test, compares differences by proximal, distal, and rectal tumors.
b
CIMP-: 0 or 1 of 5 markers methylated; CIMP+: 2 or more of 5 markers methylated.